Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT01710410

Transcranial Direct Current Stimulation in a Smoking Cessation Trial

Pilot Study of Transcranial Direct Current Stimulation (tDCS) as a Smoking Cessation Treatment for Nicotine Dependent Smokers

Status
Withdrawn
Phase
Phase 2
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Centre for Addiction and Mental Health · Academic / Other
Sex
All
Age
19 Years – 55 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine the effectiveness of transcranial direct current stimulation (tDCS) plus nicotine patch as a viable smoking cessation program for nicotine dependent smokers.

Detailed description

BACKGROUND: Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation that involves the application of brief weak electric current to the scalp. tDCS may induce neuroplasticity, thereby engaging some of the same systems that figure prominently in the pathological neuroplasticity caused by addictive drugs. OBJECTIVE: To assess whether tDCS delivered along with nicotine patch reliably increases a) quit rates, b) duration of abstinence, and c) percentage of participants abstinent at follow-up. METHOD: Active (20min; 2mA) and sham (30sec; 2mA) stimulation will be applied to the dorsolateral prefrontal cortex (DLPFC) in both cerebral hemispheres. HYPOTHESES: 1. Active tDCS (20-min; 2 mA) will increase abstinence in a standard smoking cessation protocol relative to a sham procedure. 2. The benefits of active left anodal stimulation (anode-left/cathode-right) to the DLPFC will be greater than of active tDCS in the reverse configuration (cathode-left/anode-right).

Conditions

Interventions

TypeNameDescription
DEVICEactive transcranial Direct Current StimulationBrief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
DEVICEsham transcranial Direct Current StimulationBrief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.

Timeline

Start date
2016-10-01
Primary completion
2016-10-01
Completion
2016-10-01
First posted
2012-10-19
Last updated
2016-06-13

Locations

1 site across 1 country: Canada

Source: ClinicalTrials.gov record NCT01710410. Inclusion in this directory is not an endorsement.